MRKMerck Sharp & Dohme LLCRunning, no new patients
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
Urinary Bladder Cancer, Muscle-invasive
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 595 (final count)
- Started
- Jul 24, 2019
- Main results expected
- Jun 6, 2025
- Fully finished
- Dec 15, 2027
- Results posted
- Jun 30, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone
Measured over: Up to approximately 53 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03924895 · record last updated 2026-06-30 · checked 2026-11-09 15:47 UTC